title: Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.
abstract: Neuropeptides appear to play a role in the pathophysiology of depression and electroconvulsive treatment and lithium affect these compounds in human cerebrospinal fluid (CSF) and rodent brain. Consequently, we investigated whether long-term treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram (Cit) would also affect neuropeptides in CSF of depressed patients. Changes in CSF monoamine metabolites were also explored. CSF concentrations of corticotropin-releasing hormone (CRH)-like immunoreactivity (-LI), neuropeptide Y (NPY)-LI, and Cit were determined in 21 patients with major depression. Lumbar puncture was performed in the morning at baseline and was repeated after at least 4 wk of Cit treatment (40 mg/d). The severity of depression was assessed by the Hamilton Rating Scale for Depression (HAMD). Cit treatment was associated with a significant increase in NPY-LI and decrease in CRH-LI. An evaluation of the relationship between changes in concentrations of NPY-LI, CRH-LI, and the clinical response showed significant correlations between these parameters. Significant NPY and CRH changes in CSF following treatment as well as correlations to changes in HAMD support the hypothesis that these two peptides play a role in affective disorders and are markers of therapeutic response.
authors.affiliation: Department of Psychiatry and Psychotherapy, Klinikum Fulda, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Nikisch
authors.forename: Hans
authors.initials: H
authors.lastname: Agren
authors.forename: Chin B
authors.initials: CB
authors.lastname: Eap
authors.forename: Adelheid
authors.initials: A
authors.lastname: Czernik
authors.forename: Pierre
authors.initials: P
authors.lastname: Baumann
authors.forename: Aleksander A
authors.initials: AA
authors.lastname: Mathé
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use*; D003346:Corticotropin-Releasing Hormone / Q000097:blood / Q000134:cerebrospinal fluid*; D003863:Depression / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood / Q000134:cerebrospinal fluid*; D013997:Time Factors
chemical_list: D018687:Antidepressive Agents, Second-Generation; D009478:Neuropeptide Y; D015283:Citalopram; D003346:Corticotropin-Releasing Hormone